Crohns Disease Genetic Marker Anti-TNF: 3 Alarming New Findings
The largest study ever conducted on why anti-TNF drugs fail patients with Crohns disease has identified a genetic marker that could transform how treatment decisions are made. A UK-wide collaboration led by the University of Exeter, Royal Devon and Exeter NHS Foundation Trust, and the Wellcome Sanger Institute has shown that a Crohns disease genetic marker carried by 40% of the European population doubles the risk of developing antibodies against the drugs infliximab and adalimumab, leading to loss of treatment response. Published in Gastroenterology, the findings were part funded by Wellcome, Crohns and Colitis UK, Guts UK, and Cure Crohns Colitis. According to the Mayo Clinic, Crohns disease is a chronic inflammatory bowel condition with no cure, making personalized treatment strategies essential to improving long term outcomes.
What Are Anti-TNF Drugs and Why Do They Fail
Anti-tumor necrosis factor drugs, including infliximab and adalimumab, are used to treat patients with moderate to severe Crohns disease and ulcerative colitis when other treatments have not worked. These biological medicines function by blocking TNF, a protein that drives persistent gut inflammation. Introduced in the 1990s, anti-TNF drugs now rank among the top five drugs by spend in the UK National Health Service.
Despite their importance, many patients lose response to anti-TNF treatment over time. One of the primary drivers of this treatment failure is immunogenicity, a process in which the immune system begins to recognize the drug as a threat rather than a medicine. Because anti-TNF drugs are large, complex molecules produced inside living cells, repeated administration can trigger antibody production against the drug. These antibodies accelerate how quickly the drug is cleared from the body, reducing its effectiveness and sometimes causing adverse reactions at the time of injection or infusion. The Crohns disease genetic marker identified in this study explains a significant portion of why this happens.
The PANTS Study: Largest Cohort of Its Kind
The Personalised Anti-TNF Therapy in Crohns Disease study, known as PANTS, analyzed the clinical data and genetics of 1,240 patients with Crohns disease beginning anti-TNF treatment across 120 UK hospitals. This makes it the largest study of its kind ever conducted, providing a level of statistical power that previous research in this area could not achieve.
The Crohns disease genetic marker identified through PANTS is called HLA-DQA1*05. It is present in approximately 40% of the European population and was found to double the risk of developing antibodies against both infliximab and adalimumab. This finding provides a concrete biological explanation for a pattern of treatment failure that clinicians have observed for decades without being able to predict in advance.
3 Alarming Findings From the Crohns Disease Genetic Marker Study
1. A Single Genetic Variant Doubles the Risk of Treatment Failure
The identification of HLA-DQA1*05 as a Crohns disease genetic marker that increases immunogenicity risk two-fold is one of the most clinically actionable findings in inflammatory bowel disease research in years. Because 40% of the European population carries this variant, a substantial proportion of patients starting anti-TNF therapy are at significantly elevated risk of developing the antibodies that cause treatment failure. Genetic testing before treatment could identify these patients and allow clinicians to choose alternative therapies from the outset.
2. Personalized Treatment Decisions Are Now Within Reach
The PANTS investigators conclude that a further trial is required to confirm that pre-treatment genetic testing will reduce treatment failure rates in practice. However, the Crohns disease genetic marker discovery already provides a scientifically validated basis for a pharmacogenetic approach to anti-TNF therapy. As Helen Terry, Director of Research at Crohns and Colitis UK, stated, the future of Crohns and Colitis treatment is personalized medicine, and this identification of a genetic marker that explains why anti-TNF drugs fail some patients is highly significant.
3. The Research Is Part of a Broader Precision Medicine Initiative
The PANTS study is part of a program committed to finding the right drug for the right patient the first time. The Crohns disease genetic marker research exemplifies the direction that inflammatory bowel disease treatment is heading, moving away from trial and error prescribing toward genetically informed decision making. As Professor Tariq Ahmad, Head of the Inflammatory Bowel Disease and Pharmacogenetics Research Group at the University of Exeter, noted, this type of research is essential to developing cost effective treatment strategies for patients with inflammatory bowel disease.
The Growing Burden of Crohns Disease
Crohns disease causes inflammation and ulceration throughout the digestive system and most commonly presents in young adults, adolescents, and children. There are approximately 160,000 patients with Crohns disease in the UK alone, and that number is growing. Symptoms include urgent diarrhea, rectal bleeding, abdominal pain, profound fatigue, and weight loss. For patients who do not respond to available therapies, the impact on quality of life is severe and sustained.
FOMAT conducts Phase I through Phase IV clinical research across a national network of investigator sites throughout the United States. To learn more about active gastroenterology studies, visit our patient active studies page.